# Cyrela Brazil Realty Empreendimentos e Participações Valuation

Is CYRE3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6Valuation Score 4/6

Below Fair Value

Significantly Below Fair Value

Price-To-Earnings vs Peers

Price-To-Earnings vs Industry

Price-To-Earnings vs Fair Ratio

Analyst Forecast

## Share Price vs Fair Value

What is the Fair Price of CYRE3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CYRE3 (R$21.77) is trading below our estimate of fair value (R$23.56)

Significantly Below Fair Value: CYRE3 is trading below fair value, but not by a significant amount.

## Key Valuation Metric

Which metric is best to use when looking at relative valuation for CYRE3?

Other financial metrics that can be useful for relative valuation.

What is CYRE3's n/a Ratio? | |
---|---|

n/a | 0x |

n/a | n/a |

Market Cap | R$8.16b |

Key Statistics | |
---|---|

Enterprise Value/Revenue | 1.7x |

Enterprise Value/EBITDA | 11.7x |

PEG Ratio | 4.3x |

## Price to Earnings Ratio vs Peers

How does CYRE3's PE Ratio compare to its peers?

Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|

Peer Average | 11.1x | ||

DIRR3 Direcional Engenharia | 11.8x | 21.9% | R$5.0b |

CURY3 Cury Construtora e Incorporadora | 11.6x | 17.6% | R$6.8b |

EZTC3 EZTEC Empreendimentos e Participações | 11.6x | 22.7% | R$3.1b |

PLPL3 Plano & Plano Desenvolvimento Imobiliário | 9.3x | 20.8% | R$2.5b |

CYRE3 Cyrela Brazil Realty Empreendimentos e Participações | 7.8x | 1.8% | R$8.2b |

Price-To-Earnings vs Peers: CYRE3 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the peer average (11.1x).

## Price to Earnings Ratio vs Industry

How does CYRE3's PE Ratio compare vs other companies in the South American Consumer Durables Industry?

Price-To-Earnings vs Industry: CYRE3 is good value based on its Price-To-Earnings Ratio (7.8x) compared to the Global Consumer Durables industry average (14.9x).

## Price to Earnings Ratio vs Fair Ratio

What is CYRE3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Fair Ratio | |
---|---|

Current PE Ratio | 7.8x |

Fair PE Ratio | 7x |

Price-To-Earnings vs Fair Ratio: CYRE3 is expensive based on its Price-To-Earnings Ratio (7.8x) compared to the estimated Fair Price-To-Earnings Ratio (7x).

## Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|

Current | R$21.77 | R$28.82 +32.4% | 10.8% | R$33.00 | R$23.00 | n/a | 12 |

Aug ’25 | R$19.61 | R$29.07 +48.2% | 10.3% | R$33.00 | R$23.00 | n/a | 12 |

Jul ’25 | R$18.61 | R$29.07 +56.2% | 11.0% | R$33.00 | R$23.00 | n/a | 11 |

Jun ’25 | R$19.11 | R$29.07 +52.1% | 10.5% | R$33.00 | R$23.00 | n/a | 12 |

May ’25 | R$20.30 | R$29.48 +45.2% | 10.8% | R$33.00 | R$23.00 | n/a | 12 |

Apr ’25 | R$24.45 | R$29.06 +18.9% | 11.5% | R$33.00 | R$21.00 | n/a | 13 |

Mar ’25 | R$24.47 | R$28.52 +16.6% | 11.1% | R$33.00 | R$21.00 | n/a | 13 |

Feb ’25 | R$22.62 | R$27.68 +22.4% | 15.3% | R$33.00 | R$18.00 | n/a | 13 |

Jan ’25 | R$24.08 | R$27.06 +12.4% | 14.5% | R$32.00 | R$18.00 | n/a | 13 |

Dec ’24 | R$22.21 | R$27.06 +21.8% | 14.5% | R$32.00 | R$18.00 | n/a | 13 |

Nov ’24 | R$18.29 | R$25.37 +38.7% | 16.1% | R$30.00 | R$17.00 | n/a | 13 |

Oct ’24 | R$20.27 | R$24.33 +20.0% | 16.3% | R$30.00 | R$17.00 | n/a | 13 |

Sep ’24 | R$22.79 | R$23.89 +4.8% | 15.6% | R$30.00 | R$17.00 | n/a | 14 |

Aug ’24 | R$23.52 | R$22.37 -4.9% | 13.7% | R$28.00 | R$17.00 | R$19.61 | 13 |

Jul ’24 | R$20.13 | R$20.23 +0.5% | 11.4% | R$23.00 | R$15.00 | R$18.61 | 12 |

Jun ’24 | R$18.95 | R$19.78 +4.4% | 10.4% | R$22.00 | R$15.00 | R$19.11 | 12 |

May ’24 | R$15.45 | R$20.38 +31.9% | 15.7% | R$28.00 | R$15.00 | R$20.30 | 14 |

Apr ’24 | R$14.08 | R$20.95 +48.8% | 18.0% | R$29.00 | R$15.00 | R$24.45 | 15 |

Mar ’24 | R$14.86 | R$21.50 +44.7% | 17.5% | R$29.00 | R$15.00 | R$24.47 | 13 |

Feb ’24 | R$14.97 | R$22.42 +49.8% | 15.7% | R$29.00 | R$18.00 | R$22.62 | 13 |

Jan ’24 | R$13.07 | R$23.04 +76.3% | 15.0% | R$29.00 | R$18.00 | R$24.08 | 13 |

Dec ’23 | R$14.09 | R$23.88 +69.5% | 13.7% | R$29.00 | R$19.50 | R$22.21 | 13 |

Nov ’23 | R$18.59 | R$23.92 +28.7% | 13.5% | R$29.00 | R$20.00 | R$18.29 | 13 |

Oct ’23 | R$18.35 | R$23.54 +28.3% | 15.8% | R$29.00 | R$18.00 | R$20.27 | 13 |

Sep ’23 | R$15.14 | R$22.33 +47.5% | 20.5% | R$30.00 | R$15.00 | R$22.79 | 12 |

Aug ’23 | R$12.93 | R$22.45 +73.7% | 21.3% | R$30.00 | R$15.00 | R$23.52 | 11 |

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.